Skip to main content

Table 2 The difference of bone mineral density and bone turnover marker during study period

From: The impact of sequential therapy from short-term teriparatide to denosumab compared with denosumab alone in patients with osteoporotic hip fracture: a 1-year follow-up study

 

Difference between before and after treatment

(mean ± SD)

p-value

Hip BMD (g/cm2)

 group 1

−0.01 ± 0.03

0.147

 group 2

0.007 ± 0.04

 

Femoral neck BMD (g/cm2)

 group 1

0.005 ± 0.04

0.442

 group 2

−0.014 ± 0.10

 

Spine BMD (g/cm2)

 group 1

0.043 ± 0.05

0.640

 group 2

0.052 ± 0.06

 

Serum osteocalcin (ng/mL)

 group 1

0.39 ± 3.25

0.764

 group 2

−0.33 ± 1.85

 

Serum CTX (ng/mL)

 group 1

−0.30 ± 0.55

0.252

 group 2

−0.09 ± 0.28

 
  1. BMD bone mineral density; CTX C-terminal telopetide